Privacy Policy
Signals Blog

Contributors

Categories

What drives research in the field of biomaterials? Second in series

by | May 11, 2015

. An interview with Professor John E. Davies, University of Toronto. By Hamideh Emrani The second post, in my interview series with biomaterials experts, is with my Master’s supervisor, Professor John (JED) Davies. He is an internationally recognized leader in bone...

Right Turn: Are you an entrepreneur at heart?

by | May 1, 2015

. So you’ve developed an amazing regenerative medicine device or cell therapy, or you’ve discovered a molecule that you believe could eventually be developed into a drug for awakening stem cells in the body. What’s next? For some scientists, the next step could...

What drives research in the field of biomaterials?

by | Apr 22, 2015

. By Hamideh Emrani It always feels amazing to find a solution to a problem or challenge. I think this huge sense of accomplishment is what drives many people in the research community. During my academic career, I have come across some remarkable scientists and...

Regenerative Medicine Deal Review: March

by | Apr 13, 2015

. Welcome to your deal review for the month of March. Cellular Dynamics threw shareholders for a loop after making a seemingly hasty decision to sell the company off to Fujifilm in a $307* million deal. Merck and synthetic biology specialist Intrexon announced a...

Update from the Clinic: March

by | Apr 7, 2015

. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...

Update from the Clinic: February

by | Mar 25, 2015

. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...